Carfilzomib, Bendamustine, And Dexamethasone (Kbd) In Advanced Multiple Myeloma: The Emn09-Trial.

8019Background: Various new agents have been introduced recently to treat relapsed/refractory multiple myeloma (RRMM), yet the chronification of the disease requires additional options for patients (pts) in advanced stages. Here, effectiveness and tolerability are important. Many advanced pts have received little chemotherapy but may suffer from peripheral neuropathy (PN). Carfilzomib (K) is a potent novel proteasome inhibitor not inducing significant PN. K was combined with bendamustine (B) to achieve synergistic effects. KB with low-dose dexamethasone (d) was tested in RRMM pts in a phase 1/2 trial (NCT02056756). Methods: 63 RRMM pts with ≥2 lines of prior therapy received KBd. Therapy consisted of 8 28-day courses of B at 70 mg/m2 day 1,8; K at 27 mg/m2 (initially 20 mg/m2) day 1,2,8,9,15,16; d at 20 mg on every treatment day plus day 22,23. Responding pts received Kd maintenance every 14 days until PD. In the phase 1, a dose escalation in 6 pts to K at 36 mg/m2 was attempted but led to 2 dose limiting...